Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

• Published in: Nature microbiology Vol. 5; no. 10; pp. 1185 - 1191
• Main Authors: Lee, Wen Shi, Wheatley, Adam K., Kent, Stephen J., DeKosky, Brandon J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.10.2020; Nature Publishing Group
• Subjects: 13/1; 631/250/255; 631/61/24; Animals; Antibodies; Antibodies, Monoclonal - administration & dosage; Antibodies, Neutralizing - administration & dosage; Antibodies, Viral - administration & dosage; Antibodies, Viral - immunology; Antibody-Dependent Enhancement - immunology; Betacoronavirus - immunology; Biomedical and Life Sciences; Clinical trials; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; Coronavirus Infections - therapy; Coronaviruses; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dengue fever; Humans; Immunization, Passive - adverse effects; In Vitro Techniques; Infectious Diseases; Life Sciences; Medical Microbiology; Microbiology; Models, Immunological; Pandemics - prevention & control; Parasitology; Perspective; Pneumonia, Viral - immunology; Pneumonia, Viral - prevention & control; Pneumonia, Viral - therapy; Respiratory syncytial virus; Respiratory Tract Diseases - etiology; Respiratory Tract Diseases - immunology; Risk Factors; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccines; Viral Vaccines - adverse effects; Viral Vaccines - immunology; Virology

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 thr...